AAN 2018: Additional biomarker and vaccine responses announced for ocrelizumab in multiple sclerosis

Written by Sharon Salt, Editor

Earlier this week at the American Academy of Neurology’s (AAN) 70th Annual Meeting (21–27 April, CA, USA), neurologists from Penn Medicine (PA, USA) have presented their findings from two studies that investigate the impact of ocrelizumab in multiple sclerosis (MS) patients. In March 2017, the US FDA approved ocrelizumab as the first treatment for relapsing and progressive forms of MS. Ocrelizumab is a humanized monoclonal antibody designed to target cells expressing CD20 antigens – primarily B cells. In previous work, researchers examined the blood of patients prior to and following ocrelizumab treatment, revealing that treatment decreases the ability of the...

To view this content, please register now for access

It's completely free